SCHEMBL599822

SCHEMBL599822

Brc1cnc2n1CCC2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3549518 0.93 HPGD (0.50)
SCHEMBL950413 0.91 HPGD (0.53)
SCHEMBL8335933 0.76
SCHEMBL10234138 0.71 MAPT (0.48)
SCHEMBL21532827 0.71 AR (0.44)
SCHEMBL25320550 0.71 AR (0.44)
SCHEMBL22629629 0.71 AR (0.44)
SCHEMBL25221919 0.71 AR (0.44)
SCHEMBL25420895 0.71 P2RX7 (0.40)
SCHEMBL20360628 0.71 P2RX7 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119855817-A Heterocyclic alkynyl-substituted amide derivatives, preparation method and application thereof 成都微芯药业有限公司 2025-04-18 CN disclosed
WO-2025026381-A1 HETEROCYCLYLALKYNYL SUBSTITUTED AMIDE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF 成都微芯药业有限公司 2025-02-06 WO disclosed
WO-2023132369-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT 中外製薬株式会社 2023-07-13 WO disclosed
WO-2023096850-A1 PHOSPHOINOSITIDE 3 KINASE GAMMA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF GEODE THERAPEUTICS INC. (US) 2023-06-01 WO disclosed
US-10961238-B2 Modulators of hedgehog (Hh) signaling pathway E-THERAPEUTICS PLC (GB) 2021-03-30 US disclosed
CN-107406436-B Tetrahydropyranyl benzamide derivatives 伊莱利利公司 2021-02-26 CN disclosed
US-10196385-B2 Tetrahydropyranyl benzamide derivatives ELI LILLY AND COMPANY (US) 2019-02-05 US disclosed
US-20180194755-A1 Tetrahydropyranyl Benzamide Derivatives ELI LILLY AND COMPANY 2018-07-12 US disclosed
WO-2017170765-A1 NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUND 田辺三菱製薬株式会社 2017-10-05 WO disclosed
US-20140349970-A1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC. (US) 2014-11-27 US disclosed
US-8785639-B2 Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof ABBVIE INC. (US) 2014-07-22 US disclosed
US-8785639-B2 Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof ABBVIE INC. (US) 2014-07-22 US disclosed
US-8785639-B2 Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof ABBVIE INC. (US) 2014-07-22 US disclosed
CN-102361859-A Heteroaryl compounds useful as Raf kinase inhibitors BIOGEN IDEC INC 2012-02-22 CN disclosed
US-20120040951-A1 HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. 2012-02-16 US disclosed
EP-2379513-A1 HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-10-26 EP disclosed
US-20110190489-A1 Novel Tricyclic Compounds ABBOTT LABORATORIES (US) 2011-08-04 US disclosed
US-20110190489-A1 Novel Tricyclic Compounds ABBOTT LABORATORIES (US) 2011-08-04 US disclosed
WO-2011068899-A1 NOVEL TRICYCLIC COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-09 WO disclosed
WO-2010078408-A1 HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS BIOGEN IDEC MA INC. (US) 2010-07-08 WO disclosed